Phase 3 Epilepsy Trial, Recruiting NCT07563881 Sponsor: Rapport Therapeutics Inc. Condition: Epilepsy
Back to Epilepsy

Phase 3 Epilepsy Trial, Recruiting

NCT07563881
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old
  • Your body weight falls within a healthy-to-obese range (BMI between 18 and 45) (confirm with trial site if unsure of your BMI)
  • You have been diagnosed with focal epilepsy (a type of epilepsy starting in one area of the brain) for at least 2 years before the first study visit
  • You have had at least one brain scan (MRI or CT) and one brainwave test (EEG) done within the last 10 years that support your focal epilepsy diagnosis
  • You are currently taking between 1 and 3 regular anti-seizure medications (not counting emergency or as-needed medications)
  • You are able to keep a daily electronic diary to record your seizures accurately

Who may not be able to join:

  • You have had a previous allergic reaction to, or have previously received, the study drug RAP-219
  • You have another serious medical, neurological, or mental health condition that is not well controlled or is likely to come back during the study
  • You are expected to need surgery at any point during the study
  • You have a history of generalized epilepsy (seizures affecting the whole brain, not just one area)
  • Your only type of seizure is one where you stay fully aware and have no visible symptoms (confirm with trial site)
  • You have a history of psychogenic nonepileptic seizures (seizures not caused by electrical activity in the brain)
  • You have had a prolonged seizure or uncontrollable cluster of seizures within the last 12 months
  • You have had brain surgery for epilepsy within the last 12 months
  • You have taken part in another clinical trial involving an experimental treatment within the last 12 weeks, or within 5 half-lives of that treatment, whichever is longer (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 857 323 9048

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Rapport Therapeutics Inc.
Registry
ClinicalTrials.gov
Start date
5 June 2026
Est. completion
1 July 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Median Percent Change in Seizure Frequency

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov